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Immunoglobulin light chains in uremia. the kidney and processed in a manner similar to that of
Background. Immunoglobulin light chains (IgLCs) are pro- other low molecular-weight proteins [3]. After passing
duced by B cells, slightly in excess of immunoglobulin heavy the glomerular filtration barrier, free IgLCs are reab-chains, and therefore are present in the serum of healthy adults
sorbed by proximal tubular cells, involving the bindingin free form at low concentrations. Both the  and  form of
of IgLCs to cubilin [4], a giant glycoprotein receptor,these polyclonal IgLCs are mainly metabolized by the kidney
and appear under normal conditions only in small amounts in and the megalin-mediated internalization of cubilin and
the urine. In patients with a reduced or abolished kidney func- its IgLC ligand [5]. The IgLCs are then catabolized by
tion, IgLC levels are increased. When overproduced in B cell lysosomal enzymes. As a consequence, under normallymphoproliferative disorders and deposited in the kidney,
conditions only a small amount of these polyclonal lightIgLCs can be, by themselves, a causative factor of renal diseases
chains appear in the urine.and the development of uremia.
Methods. We compared the effect of treatment with differ-
ent low- and high-flux membranes on IgLC concentrations.
The effect of free IgLCs on neutrophils, cells of the first-line SERUM CONCENTRATIONS OF FREE IGLCS
unspecific immune defense, was assessed in in vitro experi- IN UREMIA
ments.
Reduced excretion in patients with renal failure leadsResults. We found that IgLC levels in hemodialysis and hem-
odiafiltration patients were higher than in pre-dialysis patients to increased serum levels of free IgLCs [2]. Furthermore,
and that IgLC levels could not be brought into the normal a significant raise in serum concentrations of IgLC after
range by currently available hemodialysis or hemodiafiltration the start of hemodialysis (HD) therapy has been re-treatments. IgLCs interfere with chemotaxis and the activation
ported [6]. Whereas there is a negative correlation be-of glucose uptake, two essential neutrophil functions, and at-
tween IgLC concentrations and glomerular filtration ratetenuate neutrophil apoptosis, the coordinated cell death that
is crucial for the normal resolution of inflammation without (GFR) [2], there is no significant increase in the concen-
tissue destruction. trations of intact immunoglobulins in uremia [6]. Using
Conclusion. IgLCs occurring at increased levels in sera of
a newly developed assay based on Western blotting andpatients with kidney failure modulate essential functions and
enhanced chemiluminescence detection, we measuredthe apoptotic cell death of neutrophils, and as a consequence
contribute to the increased susceptibility to bacterial infections IgLC levels in chronic renal failure (CRF, pre-dialysis)
in uremic patients. and dialysis patients [7]. CRF patients had elevated total
( and ) IgLC concentrations (106  22 g/mL) as
compared with healthy controls (65  6 g/mL). In pa-
Immunoglobulin light chains (IgLCs) of - and -type tients on HD and hemodiafiltration (HDF), the treat-
are synthesized by B cells, slightly in excess of Ig heavy ment values were even higher (157  11 g/mL). We
chains [1]. Therefore, an intracellular pool of free IgLCs also compared low- and high-flux polysulfone mem-
exists within the immunoglobulin producing cells. Free branes, low- and high-flux cellulose triacetate mem-
IgLCs are also found in human plasma as a result of a branes, high-flux polymethylmethacrylate (PMMA), and
secretion parallel to the secretion of intact immunoglob- polyacrylonitrile membranes. Only dialysis with PMMA
ulins (i.e., they originate by de novo synthesis and do not membranes led to a significant reduction in IgLC concen-
represent degradation products). In plasma of healthy trations, presumably due to adsorption; however, these
people, free IgLCs exist as monomers (25 kD) and di- values did not reach control levels. However, the higher
mers (50 kD) at low concentrations and have a half-life the IgLC concentrations were at the start of the dialysis
of only 2 to 4 hours [2]. They are mainly metabolized in treatment, the amount of IgLCs removed was also
higher. This observation suggests the existence of two
different counteracting mechanisms influencing IgLCKey words: hemodialysis, neutrophils, apoptosis, light-chain deposi-
tion. levels during HD/HDF: the increased rate of IgLC ap-
pearance due to the dialysis treatment per se by a yet 2003 by the International Society of Nephrology
S-15
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unknown mechanism, and the IgLC removal only be- Kidney Blood Press Res 23:261, 2000). Therefore, free
IgLCs contribute to the preactivation of neutrophilscoming dominant at very high IgLC concentrations. A
similar situation was reported for 2-microglobulin [8]. characteristic for the chronic state of inflammation de-
scribed in uremia [12]. Interestingly, in immunoprolifera-Therefore, currently available dialysis treatments are
unable to normalize the elevated serum levels of IgLCs in tive disorders, such as multiple myeloma, with an over-
production of monoclonal IgLCs, an increased risk ofend-stage renal disease (ESRD) patients. In agreement
with these data, it has been recently described that nei- bacterial infections concomitant with decreased neutro-
phil functions has been reported [13].ther HD nor HDF treatment with different membranes
could bring the high IgLC concentration in a patient with Whereas essential neutrophil functions are important
for a successful immune response, any discharge of neu-primary amyloidosis even near normal levels, although a
higher removal of IgLCs during HDF was observed [9]. trophil cytotoxic products into the extracellular space
would lead to prolonged inflammation and, as a conse-Because IgLCs are part of immunoglobulins that exist in
an 1000-fold excess in normal human serum, and because quence, tissue destruction [14]. Therefore, the coordi-
nated removal of senescent neutrophils by macrophagesfree IgLCs represent only one of many factors contribut-
ing to a complex mixture of organ dysfunctions in uremic is crucial for the normal resolution of inflammation [15].
Apoptotic neutrophils with an undamaged cell mem-patients [10], attempts to specifically remove free IgLCs
seem not to be straightforward. Recently, efforts have brane (i.e., not releasing their harmful content into the
surrounding tissues) are recognized and taken up bybeen made to use new adsorption technologies to remove
uremic retention solutes. Future studies will have to show macrophages without the release of pro-inflammatory
cytokines. We tested the influence of IgLCs, commer-if these approaches are able to normalize IgLC concen-
trations. cially available and isolated from HD patients, on spon-
taneous neutrophil apoptosis by detecting morphologic
changes under the fluorescent microscope, and DNA
INFLUENCE OF FREE IGLCS ON FUNCTIONS
strand breaks and the loss of DNA content using flowAND APOPTOSIS OF NEUTROPHILS
cytometry (unpublished results) at 30 g/mL, a concen-
Our main interest is the effect of proteins accumulat- tration typically found for  and  IgLCs in the serum
ing in uremic sera on the unspecific immune response, of healthy people, and at 100 g/mL, a concentration
with a special focus on neutrophils, cells of the first-line measured in uremic sera. In all three apoptosis assays, we
unspecific immune defense. They migrate to the site of observed that IgLCs increased the percentage of viable
infection, attracted by chemotactic stimuli derived from neutrophils by inhibiting apoptosis in a concentration-
bacteria or from mitochondria of damaged tissues. After dependent manner. There was no difference in the ef-
the ingestion of invading bacteria by phagocytosis, neu- fects of  and  IgLCs (Fig. 1). The effect of IgLCs,
trophils kill the microorganisms by reactive oxygen inter- which has been shown to be concentration-dependent,
mediate and granule constituents in a cooperative man- could be abolished by specific antibodies. Polymyxin B,
ner. Disturbed neutrophil functions play a key role in a cationic peptide that inhibits endotoxin activity [16],
the increased risk of bacterial infections in kidney failure had no influence on the IgLC effect. Therefore, the ob-
patients. served effect is not the result of endotoxin contamina-
We tested the effect of both free polyclonal IgLCs, tion. The presence of IgLCs led to a decrease in caspase
which have been isolated from dialysis patients and 3 activity, indicating that IgLCs exert their effect via the
therefore exposed to the uremic milieu, and of commer- modulation of the activity of caspase 3, one of the central
cially available monoclonal IgLCs (Bence Jones proteins executioner enzymes activated during apoptosis in many
[BJP]), originating from the urine of multiple myeloma cell types. Genistein abolished the effect of IgLCs on
patients on neutrophils obtained from healthy donors in neutrophil apoptosis, suggesting that tyrosine phosphor-
in vitro assays. We found that both monoclonal and ylation is essential to increase neutrophil survival. Thus
polyclonal IgLCs significantly and irreversibly inhibited far, no receptor for IgLCs on neutrophils has been char-
the chemotactic movement of neutrophils toward a che- acterized. However, it has been reported that IgLCs are
motactic tripeptide, fMLP, in an in vitro assay [11]. IgLCs able to interact with B-lymphocyte membranes. The reo-
also reduced the activation of glucose uptake of neutro- rientation of the IgLCs after binding may facilitate their
phils [11], a quantitative measurement of the state of interaction with integral membrane proteins, leading to
activation of phagocytic cells. In contrast, IgLCs had no the initiation of transmembrane signaling [17].
influence on the phagocytic functions of neutrophils. The
diminished increase in neutrophil glucose uptake upon
IGLC DEPOSITION IN THE KIDNEYstimulation was partly a result of the prestimulation
caused by IgLCs. We also showed that IgLCs increase the In patients with B-cell lymphoproliferative disorders
and increased production of free IgLCs (e.g., multiplebasal levels of neutrophil oxidative metabolism (abstract;
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IgLCs, and therefore modulate amyloid fibril formation
in the kidney [23].
In conclusion, IgLCs accumulate in patients with
chronic renal failure and cannot be sufficiently removed
by currently available dialysis treatments. They not only
disturb essential neutrophil functions, and thereby an
important factor in the unspecific immune response, but
modulate neutrophil apoptotic cell death. Furthermore,
IgLCs can be by themselves a causative factor of renal
diseases and the development of uremia when they are
overproduced in B-cell lymphoproliferative disorders.
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